| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. Also,FierceLifeSci will not publish next Friday, July 5, in observance of Independence Day, but we'll be back in your inbox the following week. | |
|
Featured Story | | | Tuesday, June 25, 2019 Allergan investors have been pushing for action from its management amid struggles, and AbbVie has been hunting for new revenue streams. Now, the companies are set to combine. |
|
|
Top Stories Of The Week Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from the 2019 class of top drug launches. Instead, treatments in immunology and rare genetic diseases have grabbed the limelight. Wednesday, June 26, 2019 AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan that’ll create a top-5 pharma giant. But analysts and investors were hardly impressed. Friday, June 21, 2019 Martin Shkreli settled a lawsuit he filed against his former Retrophin colleagues, claiming they “unceremoniously and illegally” ousted him in 2014. He had sought more than $30 million in damages. Monday, June 24, 2019 The feds found a solution to fears that Bristol-Myers Squibb and Celgene would corner the psoriasis market: You can have your merger, but you don’t get to keep Celgene blockbuster Otezla. Friday, June 21, 2019 A phase 2 asthma trial of Sanofi and Regeneron’s REGN3500 has met its primary endpoint. But the IL-33 antibody performed numerically worse than Dupixent and showed little promise in combination with the approved drug. Friday, June 21, 2019 Just three days after Daiichi Sankyo’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA has declined to clear the drug in the U.S. The snub comes after a series of troubles for quizartinib. Tuesday, June 25, 2019 Sanofi’s newly appointed chief digital officer, Ameet Nathwani, M.D., isn’t surprised to see CDOs proliferating across Big Pharma. But he does think he and his counterparts have some work to do if they want to stick around. Monday, June 24, 2019 Adding OnKure’s HDAC-inhibiting drug, OKI-179, overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, a University of Colorado team found. Tuesday, June 25, 2019 A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life. The plant near Boulder, Colorado, will be converted to produce CBD products from hemp by a company riding that wave. Friday, June 21, 2019 They say you are what you eat, but some scientists may be taking that maxim a step further. To build the complex vascular channels around 3D-printed lungs, the researchers used a liquid hydrogel solution that solidifies when exposed to blue light. Resources Sponsored by: Elemental Machines How can the Internet of Things (IoT) enable you to meet GxP? Sponsored by: Veradigm Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities. Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. |
|
